小柯机器人

多基因结构可预测药物性肝损伤
2020-09-12 13:30

日本横滨市立大学Takanori Takebe团队发现,多基因结构可预测药物性肝损伤。相关论文于2020年9月7日在线发表在《自然—医学》杂志上。

通过汇总以前大规模全基因组关联研究中确定的众多全基因组基因座效应,研究人员为药物性肝损伤(DILI)建立了多基因风险评分(PRS)。在接受fasiglifam、阿莫西林-克拉维酸盐或氟氯西林治疗的患者中以及在多名供体来源的肝细胞和干细胞类器官中使用十多种不同药物处理后,PRS预测了DILI的敏感性。路径分析突出显示了以前与DILI有关的过程,包括未折叠的蛋白质反应和氧化应激。
 
在计算机筛选中,鉴定出的化合物会引起PRS升高的个体在肝细胞中出现的转录组特征,从而支持机制联系并为新型候选药物的安全性提供了新颖的筛选方法。这种遗传、细胞、类器官和人类规模的证据强调了DILI在肝细胞水平上潜在的多基因结构,从而促进了未来的机理研究。此外,这一策略可能会促进更安全、更有效和更可靠的临床试验设计。
 
据悉,DILI是终止药物开发计划以及将药物从市场中撤出的主要原因。这部分是由于无法识别有风险的患者。
 
附:英文原文

Title: Polygenic architecture informs potential vulnerability to drug-induced liver injury

Author: Masaru Koido, Eri Kawakami, Junko Fukumura, Yui Noguchi, Momoko Ohori, Yasunori Nio, Paola Nicoletti, Guruprasad P. Aithal, Ann K. Daly, Paul B. Watkins, Hisashi Anayama, Yvonne Dragan, Tadahiro Shinozawa, Takanori Takebe

Issue&Volume: 2020-09-07

Abstract: Drug-induced liver injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market; this is partially due to the inability to identify patients who are at risk1. In this study, we developed a polygenic risk score (PRS) for DILI by aggregating effects of numerous genome-wide loci identified from previous large-scale genome-wide association studies2. The PRS predicted the susceptibility to DILI in patients treated with fasiglifam, amoxicillin–clavulanate or flucloxacillin and in primary hepatocytes and stem cell-derived organoids from multiple donors treated with over ten different drugs. Pathway analysis highlighted processes previously implicated in DILI, including unfolded protein responses and oxidative stress. In silico screening identified compounds that elicit transcriptomic signatures present in hepatocytes from individuals with elevated PRS, supporting mechanistic links and suggesting a novel screen for safety of new drug candidates. This genetic-, cellular-, organoid- and human-scale evidence underscored the polygenic architecture underlying DILI vulnerability at the level of hepatocytes, thus facilitating future mechanistic studies. Moreover, the proposed ‘polygenicity-in-a-dish’ strategy might potentially inform designs of safer, more efficient and robust clinical trials.

DOI: 10.1038/s41591-020-1023-0

Source: https://www.nature.com/articles/s41591-020-1023-0

Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:87.241
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex


本期文章:《自然—医学》:Online/在线发表

分享到:

0